Navigation Links
MultiVu Video Feed: POSITIVE PHASE 3 TRIAL DATA FOR INVESTIGATIONAL NEW MIGRAINE TREATMENT PRESENTED IN LATE-BREAKING SESSION AT 14th ANNUAL INTERNATIONAL HEADACHE SOCIETY CONGRESS
Date:9/10/2009

LEVADEX Analysis Shows Potential to Treat a Broad Spectrum of Migraine ***UPDATED SATELLITE COORDINATES***

Migraine is a common, debilitating neurological disorder that affects approximately 30 million people in the United States, according to the National Headache Foundation. Limitations of oral triptans, the class of prescription drugs widely used for migraines, include slow onset of significant pain relief between 45 and 90 minutes, substantial variability in patient response and side effects such as heightened blood pressure.

MAP Pharmaceuticals, Inc. will present analysis of data from the efficacy portion of the first Phase 3 trial of LEVADEX(TM) at the 14th Congress of the International Headache Society. Data from this Phase 3 trial show the potential of LEVADEX to be effective in treating acute migraine as well as a broad spectrum of migraine, including migraine subpopulations that are often resistant to current therapies, migraine with moderate and severe pain, migraine with nausea and vomiting, and migraine with and without aura. LEVADEX is an orally inhaled migraine therapy that patients administer themselves using the company's proprietary TEMPO(R) inhaler.

    SATELLITE FEED:
    Thursday, September 10th, 2009
    2:00 PM - 2:15 PM ET
    Galaxy 19
    C-Band
    Transponder 10
    Downlink Freq. 3900 Horizontal

NEWS: New Data Presented at the International Headache Society's Annual Congress Suggests New, Investigational Migraine Treatment Could Help Provide Relief for 30 Million Sufferers in the U.S.

FORMAT: B-roll and Soundbites

ADDITIONAL RESOURCES: Video, contact information and more available at: http://www.prnewswire.com/broadcast/40023/consumer.html


    SOUNDBITES:
    * Dr. Stephen Silberstein, Director of the Headache Center, Jefferson
      University Hospitals
    * Migraine patient

    B-ROLL INCLUDES:
    * Dr/Patient footage
    * MAP corporate headquarters - exteriors and lab footage
    * manufacturing footage
    * product shots

VIDEO PROVIDED BY: MAP Pharmaceuticals, Inc.

Contact: FOR MORE INFORMATION, PLEASE CALL: MultiVu Media Relations, 1-800-653-5313 EXT. 3


'/>"/>
SOURCE MAP Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. MultiVu Video Feed: Major Trial Demonstrates Comparable Accuracy of Virtual Colonoscopy and Standard Colonoscopy
2. MultiVu Video Feed: Large, Long-Term Veterans Affairs Diabetes Trial (VADT) Reveals Important Cardiovascular Safety News on AVANDIA
3. Video: MADIT-CRT Trial Results Provide Clinical Evidence That Cardiac Resynchronization Therapy Significantly Slows Heart Failure Progression
4. Video: FDA Approves INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia
5. Medigus and Tower Semiconductor Announce Worlds Smallest Medical Video Camera Based on Advanced CMOS Image Sensor
6. Video: New Dove(R) Body Washes with NutriumMoisture(TM) Restore Skins Natural Moisture
7. Video: Phase III Study Data With Vandetanib (Zactima(TM)) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Presented at American Society of Clinical Oncology
8. Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types
9. Video: UCB Launches Vimpat(R) in the U.S. for Add-On Treatment of Epilepsy in Adults
10. Video: Partnership Unites UCB with Consumer Product Innovator OXO(R)
11. VIDEO from Medialink and the Epilepsy Foundation: New Study Suggests Different Versions of the Same Epilepsy Medication Can Be Harmful
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... Minn. , Jan. 18, 2017  EnteroMedics ... of medical devices using neuroblocking technology to treat ... announced the pricing of an underwritten public offering ... prior to deducting underwriting discounts and commissions and ... offering is comprised of Class A Units, priced ...
(Date:1/18/2017)... Research and Markets has announced the addition of the "Vital ... Analysis and Industry Forecast, 2014-2022" report to their offering. ... Vital signs monitoring market size was ... by 2022, growing at a CAGR of 5.8% from 2016 to 2022. ... regional market in global vital signs monitoring devices industry. The blood pressure ...
(Date:1/18/2017)... 18, 2017   Spotlight Innovation Inc. ... plans, in the second quarter of 2017, to ... intended to provide relief from chronic pain, is ... It was developed under a licensing agreement with ... derived from snake venom. Additionally, Caretta Therapeutics has ...
Breaking Medicine Technology:
(Date:1/19/2017)... ... 19, 2017 , ... Rountree Brady Insurance Agency, a Savannah ... eastern Georgia, is embarking on a charity effort to raise awareness and gather ... every year than anything else, yet risk factors associated with heart disease are ...
(Date:1/19/2017)... , ... January 19, 2017 , ... ... the 2017 Spring Create Real Impact contest from Impact Teen Drivers and California ... http://www.createrealimpact.com . , Educational grants totaling $15,000 will be awarded for ...
(Date:1/19/2017)... ... January 19, 2017 , ... The 21st Century Cures Act’s ... FDAnews Webinar**, Jan. 26, 2016 — 1:30 p.m. – 3:00 p.m. ET, http://www.fdanews.com/21stcenturycures ... Cures Act in order to thrive this year? , The passage of the act ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... Proctology) announced today the opening of 3 medical offices specializing specifically in ... Center of Los Angeles (Beverly Hills), Hemorrhoids Center of Newport Beach, and ...
(Date:1/18/2017)... ... January 18, 2017 , ... Visually learn facts ... doctor-recommended OTC antiperspirant, Certain Dri. , Excessive sweating and hyperhidrosis are common conditions ... this infographic to explain the seven types of hyperhidrosis. This visual creates awareness ...
Breaking Medicine News(10 mins):